Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small ...

The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine. In the studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Presentation Details: Session Type: Research ForumSession Title: Gut Instincts: Exploring the Interplay of the Microbio ...

Execution Version Exhibit 10.1 EVOGENE LTD. $7.3 Million of Ordinary Shares (par value NIS 0.02 per share) Sales Agreement March 28, 2024 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Evogene Ltd., a company organized under the laws of the State of Israel (the "Company"), confirms its agreement (this "Agreement") with Lake Street Capital Markets, LLC (the "Agent"), as follows: 1. Issuance and Sale of Shares. The Company agrees that, fr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2023 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION ...

"We believe that regenerative agriculture is an integral part of addressing climate change and creating positive outcomes for both our farm partners and our planet", said Carlos Paz, President and CEO at Ceres Global Ag Corp. "By collaborating with Lavie Bio, we are well-positioned to foster more efficient growing practices and continue to offer tailored solutions to strategic customers". Lavie Bio is focused on transformation of the crop input sector through the development of biologicals as alternatives f ...

Evogene Ltd. (NASDAQ:EVGN) Q4 2023 Results Conference Call March 7, 2024 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Yoash Zohar - CEO of Casterra Conference Call Participants Ben Klieve - Lake Street Capital Ben Haynor - Alliance Global Partners Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's Fourth Quarter and Full Year 2023 Results Conference Call. All particip ...

Evogene (EVGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this agricultural company would post a loss of $0.17 per share when it actually produced a loss of $0.08, delivering a surprise of 52.94%.Over the last four quarters, the company has surp ...

These agreements are expected to add approximately 400 tons in 2024 and establish long-term production infrastructure. Expanding the number of seed producers in various geographies with whom the company currently works is expected to lower production risks. Casterra's high-yield castor seed varieties, developed with Evogene's GeneRator AI tech-engine, are rigorously tested to meet industry standards. They are distinguished by exceptional cleanliness, successful phytosanitary test results, and an exceptional ...

Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Thursday, March 7th, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 ...

In collaboration with Bayer's Crop Science division, having an industry-leading R&D pipeline and portfolio of seeds & traits, crop protection, and digital farming solutions, AgPlenus will use its AI-driven computational modeling technology to design and optimize molecules identified for their broad-spectrum herbicidal activity targeting the APTH1 protein, a new mode of action identified by AgPlenus. Herbicide market is valued at $42.81 billion in 2024[1] and is crucial for ensuring global food security. It ...